Back to Search
Start Over
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment.
- Source :
-
NPJ Parkinson's disease [NPJ Parkinsons Dis] 2023 Apr 24; Vol. 9 (1), pp. 68. Date of Electronic Publication: 2023 Apr 24. - Publication Year :
- 2023
-
Abstract
- Pathophysiological substrate(s) and progression of Parkinson's disease (PD) with mild cognitive impairment (PD-MCI) are still matter of debate. Baseline cerebrospinal fluid (CSF) neurochemical profile and cognitive changes after 2 years were investigated in a retrospective series of PD-MCI (n = 48), cognitively normal PD (PD-CN, n = 40), prodromal Alzheimer's disease (MCI-AD, n = 25) and cognitively healthy individuals with other neurological diseases (OND, n = 44). CSF biomarkers reflecting amyloidosis (Aβ42/40 ratio, sAPPα, sAPPβ), tauopathy (p-tau), neurodegeneration (t-tau, NfL, p-NfH), synaptic damage (α-syn, neurogranin) and glial activation (sTREM2, YKL-40) were measured. The great majority (88%) of PD-MCI patients was A-/T-/N-. Among all biomarkers considered, only NfL/p-NfH ratio was significantly higher in PD-MCI vs. PD-CN (p = 0.02). After 2 years, one-third of PD-MCI patients worsened; such worsening was associated with higher baseline levels of NfL, p-tau, and sTREM2. PD-MCI is a heterogeneous entity requiring further investigations on larger, longitudinal cohorts with neuropathological verification.<br /> (© 2023. The Author(s).)
Details
- Language :
- English
- ISSN :
- 2373-8057
- Volume :
- 9
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- NPJ Parkinson's disease
- Publication Type :
- Academic Journal
- Accession number :
- 37095141
- Full Text :
- https://doi.org/10.1038/s41531-023-00509-w